Alnylam Pharmaceuticals, Inc. Earnings

Alnylam Pharmaceuticals, Inc.’s revenue jumped 17.26% since last year same period to $773.69Mn in the Q2 2025. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated 30.21% jump in its revenue since last 3-months.

Alnylam Pharmaceuticals, Inc.’s net profit fell -292.43% since last year same period to $-66.28Mn in the Q2 2025. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated -15.31% fall in its net profits since last 3-months.

Alnylam Pharmaceuticals, Inc.’s net profit margin fell -234.67% since last year same period to -8.57% in the Q2 2025. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated 11.45% jump in its net profit margins since last 3-months.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 1.39 - a 826.67% jump from last quarter’s estimates.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 1.39.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Alnylam Pharmaceuticals, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.